Published 7 days ago • loading... • Updated 7 days ago

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

On Monday, Neurocrine Biosciences announced new clinician survey data showing INGREZZA improves involuntary movements in patients with mild tardive dyskinesia in real-world settings.
Affecting at least 800,000 U.S. adults, tardive dyskinesia is a movement disorder often resulting from antipsychotic medications used to treat mental health conditions like schizophrenia and depression.
Clinicians reported that 90% of patients with mild TD experienced functional impairment before treatment; following INGREZZA initiation, 96% showed improvement in uncontrolled movements, with 86% improving within four weeks.
Beyond movement improvements, 70% of employed or student patients experienced better willingness to work or attend school. "Even tardive dyskinesia identified as mild in severity can meaningfully disrupt patients' daily functioning," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences.
Presented at the American Psychiatric Association 2026 Annual Meeting in San Francisco, these findings support clinical guidelines stating treatment with INGREZZA can be considered for mild TD based on patient preference and associated impairment.

Insights by Ground AI